CorMedix: The Niche Champion in the Fight Against Catheter Infections
Reading Time: 4 minutes
CorMedix is a biopharmaceutical company focused on the development and commercialization of therapeutic products for life-threatening diseases and conditions. With its catheter lock solution DefenCath, the company has reported impressive revenue figures and regularly exceeds analysts' forecasts, indicating a successful market introduction. The clinical development of DefenCath for additional applications, including patients on total parenteral nutrition and pediatric hemodialysis patients, is advancing, significantly enhancing...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
